

Lawrence Steinman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3562413/lawrence-steinman-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

189
papers

21,374
citations

63
h-index

145
g-index

216
ext. papers

23,893
ext. citations

16.2
avg, IF

7.08
L-index

#	Paper	IF	Citations
189	Epstein-Barr virus and multiple sclerosis.. <i>Science</i> , 2022 , 375, 264-265	33.3	13
188	Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM.. <i>Nature</i> , 2022 ,	50.4	51
187	COVID-19 therapeutics: Challenges and directions for the future.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2119893119	11.5	9
186	Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2123483119	11.5	
185	Capturing pathogenic immune cells before they home to brain. <i>Med</i> , 2021 , 2, 214-216	31.7	
184	Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist. <i>ELife</i> , 2021 , 10,	8.9	4
183	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 51, 102844	4	3
182	Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	7
181	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. <i>European Journal of Neurology</i> , 2021 , 28, 3722-3730	6	2
180	Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced PANIC attack. <i>Journal of the Neurological Sciences</i> , 2020 , 415, 116935	3.2	24
179	A sugar-coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD-19: An Editorial Highlight for "Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer" on page 486. <i>Journal of Neurochemistry</i> , 2020 , 154, 465-467	6	3
178	Part I. SARS-CoV-2 triggered PANIC attack in severe COVID-19. <i>Journal of the Neurological Sciences</i> , 2020 , 415, 116936	3.2	16
177	Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. <i>Trends in Molecular Medicine</i> , 2020 , 26, 296-310	11.5	82
176	Autoimmune Diseases: The Role for Vaccines 2020 , 375-381		
175	Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	8
174	Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 24620-24626	11.5	59
173	Autoantibodies against central nervous system antigens in a subset of B cell-dominant multiple sclerosis patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 21512-21518	11.5	12

172	New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 443-459	5.9	13
171	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology</i> , 2019 , 18, 1009-1020	24.1	96
170	Antigen-specific tolerance to self-antigens in protein replacement therapy, gene therapy and autoimmunity. <i>Current Opinion in Immunology</i> , 2019 , 61, 46-53	7.8	23
169	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology</i> , 2019 , 18, 1021-1033	24.1	98
168	DNA threads released by activated CD4 T lymphocytes provide autocrine costimulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 8985-8994	11.5	14
167	Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 8463-8470	11.5	59
166	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1255-1262	5	24
165	Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation. <i>Neurotherapeutics</i> , 2019 , 16, 808-827	6.4	3
164	Small Heat Shock Proteins, Amyloid Fibrils, and Nicotine Stimulate a Common Immune Suppressive Pathway with Implications for Future Therapies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019 , 9,	5.4	4
163	Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models. <i>Nature Neuroscience</i> , 2018 , 21, 541-551	25.5	164
162	Nonclassical monocytes: are they the next therapeutic targets in multiple sclerosis?. <i>Immunology and Cell Biology</i> , 2018 , 96, 125-127	5	5
161	Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens. <i>Clinical Immunology</i> , 2018 , 187, 37-45	9	49
160	An amyloidogenic hexapeptide derived from amylin attenuates inflammation and acute lung injury in murine sepsis. <i>PLoS ONE</i> , 2018 , 13, e0199206	3.7	1
159	CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 927-936	5.5	63
158	Molecular signature of Epstein-Barr virus infection in MS brain lesions. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e466	9.1	40
157	Identification of a common immune regulatory pathway induced by small heat shock proteins, amyloid fibrils, and nicotine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 7081-7086	11.5	16
156	Blocking immune intrusion into the brain suppresses epilepsy in Rasmussen's encephalitis model. <i>Journal of Clinical Investigation</i> , 2018 , 128, 1724-1726	15.9	1
155	Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy of Duchenne dystrophy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E9182-E9191	11.5	14

154	Time correlation between mononucleosis and initial symptoms of MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e308	9.1	16
153	Phosphorylation of B-crystallin supports reactive astrogliosis in demyelination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E1745-E1754	11.5	25
152	Adrenocorticotrophic hormone methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial. <i>Therapeutic Advances in Neurological Disorders</i> , 2017 , 10, 3-17	6.6	14
151	T Cell-Transfer Experimental Autoimmune Encephalomyelitis: Pillar of Multiple Sclerosis and Autoimmunity. <i>Journal of Immunology</i> , 2017 , 198, 3381-3383	5.3	5
150	Treatment with anti-Fc γ R1 antibody exacerbates EAE and T-cell immunity against myelin. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e342	9.1	6
149	Induction of New Autoimmune Diseases After Alemtuzumab Therapy for Multiple Sclerosis: Learning From Adversity. <i>JAMA Neurology</i> , 2017 , 74, 907-908	17.2	10
148	Iron-sulfur glutaredoxin 2 protects oligodendrocytes against damage induced by nitric oxide release from activated microglia. <i>Glia</i> , 2017 , 65, 1521-1534	9	26
147	Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS. <i>Journal of Neuroinflammation</i> , 2017 , 14, 235	10.1	28
146	Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4. <i>Journal of Visualized Experiments</i> , 2017 ,	1.6	3
145	Targeting molecules involved in immune cell trafficking to the central nervous system for therapy in multiple sclerosis. <i>Clinical and Experimental Neuroimmunology</i> , 2017 , 8, 183-191	0.4	2
144	Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine. <i>Journal of Neuroimmunology</i> , 2017 , 313, 77-81	3.5	18
143	The emergence of neuroepidemiology, neurovirology and neuroimmunology: the legacies of John F. Kurtzke and Richard Dickson Johnson. <i>Journal of Neurology</i> , 2017 , 264, 817-828	5.5	1
142	Narcolepsy and influenza vaccination-induced autoimmunity. <i>Annals of Translational Medicine</i> , 2017 , 5, 25	3.2	6
141	Genetic background modulates outcome of therapeutic amyloid peptides in treatment of neuroinflammation. <i>Journal of Neuroimmunology</i> , 2016 , 298, 42-50	3.5	3
140	CEACAM1 mediates B cell aggregation in central nervous system autoimmunity. <i>Scientific Reports</i> , 2016 , 6, 29847	4.9	6
139	An interferon- β resistant and NLRP3 inflammasome-independent subtype of EAE with neuronal damage. <i>Nature Neuroscience</i> , 2016 , 19, 1599-1609	25.5	44
138	Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , 2016 , 29, 340-4	7.1	19
137	Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 1339-44	11.5	39

136	Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 1600-5	11.5	44
135	Multiplexed autoantigen microarrays identify HLA as a key driver of anti-desmoglein and -non-desmoglein reactivities in pemphigus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 1859-64	11.5	38
134	Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. <i>Neurology</i> , 2016 , 86, 382-90	6.5	90
133	A Journey in Science: The Privilege of Exploring the Brain and the Immune System. <i>Molecular Medicine</i> , 2016 , 22,	6.2	2
132	Identification of Candidate Tolerogenic CD8(+) T Cell Epitopes for Therapy of Type 1 Diabetes in the NOD Mouse Model. <i>Journal of Diabetes Research</i> , 2016 , 2016, 9083103	3.9	6
131	Anti-Insulin Immune Responses Are Detectable in Dogs with Spontaneous Diabetes. <i>PLoS ONE</i> , 2016 , 11, e0152397	3.7	7
130	Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 14781-14786	11.5	44
129	Mechanistic insights into influenza vaccine-associated narcolepsy. <i>Human Vaccines and Immunotherapeutics</i> , 2016 , 12, 3196-3201	4.4	12
128	Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 4777-82	11.5	182
127	Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. <i>Science Translational Medicine</i> , 2015 , 7, 294ra105	17.5	167
126	mir-181a-1/b-1 Modulates Tolerance through Opposing Activities in Selection and Peripheral T Cell Function. <i>Journal of Immunology</i> , 2015 , 195, 1470-9	5.3	35
125	Tissue Transglutaminase contributes to experimental multiple sclerosis pathogenesis and clinical outcome by promoting macrophage migration. <i>Brain, Behavior, and Immunity</i> , 2015 , 50, 141-154	16.6	23
124	The re-emergence of antigen-specific tolerance as a potential therapy for MS. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1223-38	5	16
123	No quiet surrender: molecular guardians in multiple sclerosis brain. <i>Journal of Clinical Investigation</i> , 2015 , 125, 1371-8	15.9	18
122	Parsing Physiological Functions of Erythropoietin One Domain at a Time. <i>Neurotherapeutics</i> , 2015 , 12, 848-9	6.4	1
121	Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 15016-23	11.5	17
120	Response to comment on "Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2". <i>Science Translational Medicine</i> , 2015 , 7, 314lr2	17.5	1
119	Self-Assembling Peptides Form Immune Suppressive Amyloid Fibrils Effective in Autoimmune Encephalomyelitis. <i>Current Topics in Behavioral Neurosciences</i> , 2015 , 26, 221-32	3.4	5

118	A century of pavlovian experiments forming a circuit from the elucidation of neural reflexes to pharmaceuticals and electroceuticals to treat diseases. <i>Brain, Behavior, and Immunity</i> , 2015 , 44, 17-8	16.6	2
117	Prolactin: a versatile regulator of inflammation and autoimmune pathology. <i>Autoimmunity Reviews</i> , 2015 , 14, 223-30	13.6	54
116	Role reversal: infiltrating T cells protect the brain. <i>Journal of Clinical Investigation</i> , 2015 , 125, 493-4	15.9	2
115	HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation. <i>Nature</i> , 2015 , 523, 342-6	50.4	142
114	CD4 cell response to interval therapy with natalizumab. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 570-4	5.3	5
113	IFN- β treatment requires B cells for efficacy in neuroautoimmunity. <i>Journal of Immunology</i> , 2015 , 194, 2110-6	5.3	50
112	B-lymphocyte-mediated delayed cognitive impairment following stroke. <i>Journal of Neuroscience</i> , 2015 , 35, 2133-45	6.6	188
111	Janus faces of amyloid proteins in neuroinflammation. <i>Journal of Clinical Immunology</i> , 2014 , 34 Suppl 1, S61-3	5.7	12
110	Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity. <i>Journal of Neuroinflammation</i> , 2014 , 11, 29	10.1	19
109	Uncovering cryptic glycan markers in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). <i>Drug Development Research</i> , 2014 , 75, 172-88	5.1	13
108	Immunology of relapse and remission in multiple sclerosis. <i>Annual Review of Immunology</i> , 2014 , 32, 257-81	31.7	217
107	Conflicting consequences of immunity to cancer versus autoimmunity to neurons: insights from paraneoplastic disease. <i>European Journal of Immunology</i> , 2014 , 44, 3201-5	6.1	12
106	Mechanisms of action of therapeutic amyloidogenic hexapeptides in amelioration of inflammatory brain disease. <i>Journal of Experimental Medicine</i> , 2014 , 211, 1847-56	16.6	11
105	Thymic epithelium determines a spontaneous chronic neuritis in Icam1(tm1Jcgr)NOD mice. <i>Journal of Immunology</i> , 2014 , 193, 2678-90	5.3	15
104	From defining antigens to new therapies in multiple sclerosis: honoring the contributions of Ruth Arnon and Michael Sela. <i>Journal of Autoimmunity</i> , 2014 , 54, 1-7	15.5	16
103	Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal. <i>Immunologic Research</i> , 2014 , 58, 307-14	4.3	8
102	Gene expression analysis of histamine receptors in peripheral blood mononuclear cells from individuals with clinically-isolated syndrome and different stages of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014 , 277, 186-8	3.5	6
101	Going viral and the fatal vulnerability of neurons from immunity, not from infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 16982-3	11.5	2

100	Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. <i>Journal of Autoimmunity</i> , 2014 , 50, 1-11	15.5	93
99	Therapeutic decisions in multiple sclerosis: moving beyond efficacy. <i>JAMA Neurology</i> , 2013 , 70, 1315-24	17.2	67
98	Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation. <i>Nature Immunology</i> , 2013 , 14, 1166-72	19.1	108
97	Weighing in on autoimmune disease: Club-and-spoke cell traffic in autoimmunity. <i>Nature Medicine</i> , 2013 , 19, 139-41	50.5	10
96	Inflammatory cytokines at the summits of pathological signal cascades in brain diseases. <i>Science Signaling</i> , 2013 , 6, pe3	8.8	37
95	Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform. <i>Clinical Immunology</i> , 2013 , 149, 297-306	9	22
94	Natalizumab: bench to bedside and beyond. <i>JAMA Neurology</i> , 2013 , 70, 172-82	17.2	91
93	The gender gap in multiple sclerosis: intersection of science and society. <i>JAMA Neurology</i> , 2013 , 70, 634-5	17.2	14
92	Interleukin 17F level and interferon γ response in patients with multiple sclerosis. <i>JAMA Neurology</i> , 2013 , 70, 1017-21	17.2	31
91	Pathogenic T helper 1 cells reach the brain before T helper 17 cells, and T regulatory cells suppress them albeit incompletely. <i>Acta Neuropathologica</i> , 2013 , 126, 517-8	14.3	1
90	CRYAB modulates the activation of CD4+ T cells from relapsing-remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1867-77	5	12
89	The interdependent, overlapping, and differential roles of type I and II IFNs in the pathogenesis of experimental autoimmune encephalomyelitis. <i>Journal of Immunology</i> , 2013 , 191, 2967-77	5.3	38
88	Piet Mondrian's trees and the evolution in understanding multiple sclerosis, Charcot Prize Lecture 2011. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 5-14	5	5
87	Nostalgia: the similarities between immunological and neurological memory. <i>Immunological Reviews</i> , 2012 , 248, 5-9	11.3	
86	Optimization of current and future therapy for autoimmune diseases. <i>Nature Medicine</i> , 2012 , 18, 59-65	50.5	61
85	Therapeutic effects of systemic administration of chaperone B-crystallin associated with binding proinflammatory plasma proteins. <i>Journal of Biological Chemistry</i> , 2012 , 287, 9708-9721	5.4	67
84	The discovery of natalizumab, a potent therapeutic for multiple sclerosis. <i>Journal of Cell Biology</i> , 2012 , 199, 413-6	7.3	46
83	Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation. <i>Science Translational Medicine</i> , 2012 , 4, 137ra73	17.5	51

82	Peroxisome proliferator-activated receptor (PPAR) α and β regulate IFN γ and IL-17A production by human T cells in a sex-specific way. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 9505-10	11.5	125
81	Lessons learned at the intersection of immunology and neuroscience. <i>Journal of Clinical Investigation</i> , 2012 , 122, 1146-8	15.9	12
80	Combining statins with interferon β in multiple sclerosis: think twice, it might not be all right. <i>Lancet Neurology</i> , 2011 , 10, 672-3	24.1	7
79	1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. <i>Molecular and Cellular Biology</i> , 2011 , 31, 3653-69	4.8	331
78	Systemic augmentation of alphaB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 13287-92	11.5	109
77	IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon- β in multiple sclerosis. <i>Science Translational Medicine</i> , 2011 , 3, 93ra68	17.5	77
76	Mixed results with modulation of TH-17 cells in human autoimmune diseases. <i>Nature Immunology</i> , 2010 , 11, 41-4	19.1	103
75	Inhibitory role for GABA in autoimmune inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 2580-5	11.5	309
74	Modulation of postoperative cognitive decline via blockade of inflammatory cytokines outside the brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 20595-6	11.5	21
73	Alphab-crystallin is a target for adaptive immune responses and a trigger of innate responses in preactive multiple sclerosis lesions. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010 , 69, 694-703	3.1	89
72	The gray aspects of white matter disease in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 8083-4	11.5	16
71	Shifting therapeutic attention in MS to osteopontin, type 1 and type 2 IFN. <i>European Journal of Immunology</i> , 2009 , 39, 2358-60	6.1	19
70	Anaphylaxis to a self-peptide in the absence of mast cells or histamine. <i>Laboratory Investigation</i> , 2009 , 89, 398-405	5.9	6
69	A molecular trio in relapse and remission in multiple sclerosis. <i>Nature Reviews Immunology</i> , 2009 , 9, 440-7	36.5	150
68	Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. <i>Nature</i> , 2008 , 451, 1076-81	50.4	406
67	New targets for treatment of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2008 , 274, 1-4	3.2	9
66	A rush to judgment on Th17. <i>Journal of Experimental Medicine</i> , 2008 , 205, 1517-22	16.6	153
65	Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. <i>Annals of Neurology</i> , 2008 , 63, 611-20	9.4	143

64	Nuanced roles of cytokines in three major human brain disorders. <i>Journal of Clinical Investigation</i> , 2008 , 118, 3557-63	15.9	88
63	Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. <i>Nature Medicine</i> , 2007 , 13, 211-7	50.5	266
62	A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. <i>Nature Medicine</i> , 2007 , 13, 139-45	50.5	1066
61	Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. <i>Nature Medicine</i> , 2007 , 13, 935-43	50.5	379
60	Antigen-specific therapy of multiple sclerosis: the long-sought magic bullet. <i>Neurotherapeutics</i> , 2007 , 4, 661-5	6.4	19
59	Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. <i>PLoS Biology</i> , 2007 , 5, e257	9.7	99
58	Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. <i>Journal of Clinical Investigation</i> , 2007 , 117, 438-47	15.9	234
57	Statins in the treatment of central nervous system autoimmune disease. <i>Journal of Neuroimmunology</i> , 2006 , 178, 140-8	3.5	55
56	How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. <i>Annals of Neurology</i> , 2006 , 60, 12-21	9.4	404
55	State of the art. Four easy pieces: interconnections between tissue injury, intermediary metabolism, autoimmunity, and chronic degeneration. <i>Proceedings of the American Thoracic Society</i> , 2006 , 3, 484-6		18
54	Controlling autoimmunity in sporadic inclusion-body myositis. <i>Neurology</i> , 2006 , 66, S56-8	6.5	5
53	Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. <i>Journal of Experimental Medicine</i> , 2006 , 203, 401-12	16.6	174
52	Nogo in multiple sclerosis: growing roles of a growth inhibitor. <i>Journal of the Neurological Sciences</i> , 2006 , 245, 201-10	3.2	17
51	A neuropeptide in immune-mediated inflammation, Y?. <i>Trends in Immunology</i> , 2006 , 27, 164-7	14.4	52
50	Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. <i>Nature Reviews Immunology</i> , 2006 , 6, 358-70	36.5	489
49	Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. <i>Journal of Clinical Investigation</i> , 2006 , 116, 1037-44	15.9	89
48	Type II HMG-CoA Reductase Inhibitors (Statins) Provide Acute-Graft-Versus-Host Disease Protection by Th-2 Cytokine Induction While Sparing Graft-Versus-Leukemia Activity.. <i>Blood</i> , 2006 , 108, 189-189	2.2	
47	Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. <i>Science</i> , 2005 , 310, 850-5	33.3	344

46	Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. <i>Trends in Immunology</i> , 2005 , 26, 565-71	14.4	190
45	Design of effective immunotherapy for human autoimmunity. <i>Nature</i> , 2005 , 435, 612-9	50.4	217
44	Drug Insight: using statins to treat neuroinflammatory disease. <i>Nature Clinical Practice Neurology</i> , 2005 , 1, 106-12		27
43	Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides. <i>International Reviews of Immunology</i> , 2005 , 24, 415-46	4.6	35
42	Immune therapy for autoimmune diseases. <i>Science</i> , 2004 , 305, 212-6	33.3	117
41	Elaborate interactions between the immune and nervous systems. <i>Nature Immunology</i> , 2004 , 5, 575-81	19.1	411
40	High-throughput methods for measuring autoantibodies in systemic lupus erythematosus and other autoimmune diseases. <i>Autoimmunity</i> , 2004 , 37, 269-72	3	28
39	Statins as potential therapeutic agents in neuroinflammatory disorders. <i>Current Opinion in Neurology</i> , 2003 , 16, 393-401	7.1	59
38	Transcriptional analysis of targets in multiple sclerosis. <i>Nature Reviews Immunology</i> , 2003 , 3, 483-92	36.5	96
37	Involvement of both Allergic and Autoimmune mechanisms in EAE, MS and other autoimmune diseases. <i>Trends in Immunology</i> , 2003 , 24, 479-84	14.4	121
36	Optic neuritis, a new variant of experimental encephalomyelitis, a durable model for all seasons, now in its seventieth year. <i>Journal of Experimental Medicine</i> , 2003 , 197, 1065-71	16.6	46
35	Protein and Peptide Array Analysis of Autoimmune Disease. <i>BioTechniques</i> , 2002 , 33, S66-S69	2.5	51
34	The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. <i>Nature</i> , 2002 , 420, 78-84	50.4	949
33	Autoantigen microarrays for multiplex characterization of autoantibody responses. <i>Nature Medicine</i> , 2002 , 8, 295-301	50.5	624
32	Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. <i>Nature Medicine</i> , 2002 , 8, 500-8	50.5	1368
31	Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. <i>Annual Review of Neuroscience</i> , 2002 , 25, 491-505	17	199
30	Millennium Award. Proteomics for the development of DNA tolerizing vaccines to treat autoimmune disease. <i>Clinical Immunology</i> , 2002 , 103, 7-12	9	31
29	Evaluating human T cell receptor gene expression by PCR. <i>Current Protocols in Immunology</i> , 2001 , Chapter 10, Unit 10.26	4	

28	An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. <i>Nature Immunology</i> , 2001 , 2, 216-22	19.1	161
27	The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. <i>Science</i> , 2001 , 294, 1731-5	33.3	729
26	Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. <i>Nature Medicine</i> , 2000 , 6, 1176-82	50.5	446
25	Idiotypic immunization induces immunity to mutated p53 and tumor rejection. <i>Nature Medicine</i> , 1998 , 4, 710-2	50.5	52
24	Some misconceptions about understanding autoimmunity through experiments with knockouts. <i>Journal of Experimental Medicine</i> , 1997 , 185, 2039-41	16.6	81
23	Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. <i>Cell</i> , 1996 , 85, 299-302	56.2	751
22	Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87-99). <i>European Journal of Immunology</i> , 1996 , 26, 2624-34	6.1	91
21	Superantigens in demyelinating disease. <i>Seminars in Immunopathology</i> , 1996 , 18, 51-6		6
20	Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. <i>Nature</i> , 1996 , 379, 343-6	50.4	349
19	Myelin basic protein peptide specificity and T-cell receptor gene usage of HPRT mutant T-cell clones in patients with multiple sclerosis. <i>Annals of Neurology</i> , 1994 , 36, 734-40	9.4	24
18	Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. <i>Nature</i> , 1993 , 365, 642-4	50.4	237
17	Autoimmune disease. <i>Scientific American</i> , 1993 , 269, 106-14	0.5	60
16	Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. <i>Nature</i> , 1993 , 362, 68-70	50.4	375
15	EAE: a model for immune intervention with synthetic peptides. <i>International Reviews of Immunology</i> , 1992 , 9, 223-30	4.6	9
14	Neoplastic and reactive human astrocytes express interleukin-8 gene. <i>Neurosurgical Review</i> , 1992 , 15, 203-7	3.9	40
13	Multiple sclerosis and its animal models: the role of the major histocompatibility complex and the T cell receptor repertoire. <i>Seminars in Immunopathology</i> , 1992 , 14, 79-93		20
12	Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. <i>Nature</i> , 1992 , 356, 63-6	50.4	1473
11	Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. <i>Nature</i> , 1992 , 356, 435-8	50.4	363

10	Myoblast transfer in DMD: problems in the interpretation of efficiency. <i>Muscle and Nerve</i> , 1992 , 15, 1209-11	3.10	21
9	An analysis of T-cell-receptor variable-region genes in tumor-infiltrating lymphocytes within malignant tumors. <i>International Journal of Cancer</i> , 1991 , 49, 545-50	7.5	21
8	Limited heterogeneity of rearranged T-cell receptor V alpha transcripts in brains of multiple sclerosis patients. <i>Nature</i> , 1990 , 345, 344-6	50.4	372
7	HTLV-I sequences are not detected in peripheral blood genomic DNA or in brain cDNA of multiple sclerosis patients. <i>Annals of Neurology</i> , 1990 , 28, 574-7	9.4	14
6	Isolation of a complementary DNA clone encoding an autoantigen recognized by an anti-neuronal cell antibody from a patient with paraneoplastic cerebellar degeneration. <i>Annals of Neurology</i> , 1990 , 28, 692-8	9.4	83
5	Prospects for specific immunotherapy in myasthenia gravis. <i>FASEB Journal</i> , 1990 , 4, 2726-31	0.9	31
4	T cell recognition in experimental autoimmune encephalomyelitis: prospects for immune intervention with synthetic peptides. <i>International Reviews of Immunology</i> , 1990 , 6, 37-47	4.6	8
3	T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. <i>Nature</i> , 1986 , 324, 258-60	50.4	434
2	T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. <i>Nature</i> , 1985 , 317, 355-8	50.4	475
1	The neuropathology of propionic acidemia. <i>Developmental Medicine and Child Neurology</i> , 1983 , 25, 87-94	3.3	14